Global Neurodegenerative Disease Market Research Report 2024(Status and Outlook)
Report Overview:
Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration of the structure and function of the nervous system, leading to cognitive and motor impairments. Examples include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
The Global Neurodegenerative Disease Market Size was estimated at USD 5843.27 million in 2023 and is projected to reach USD 7017.91 million by 2029, exhibiting a CAGR of 3.10% during the forecast period.
This report provides a deep insight into the global Neurodegenerative Disease market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Neurodegenerative Disease Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Neurodegenerative Disease market in any manner.
Global Neurodegenerative Disease Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Market Segmentation (by Type)
NMDA
SSRIs
Dopamine Inhibitors
Market Segmentation (by Application)
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurodegenerative Disease Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration of the structure and function of the nervous system, leading to cognitive and motor impairments. Examples include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
The Global Neurodegenerative Disease Market Size was estimated at USD 5843.27 million in 2023 and is projected to reach USD 7017.91 million by 2029, exhibiting a CAGR of 3.10% during the forecast period.
This report provides a deep insight into the global Neurodegenerative Disease market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Neurodegenerative Disease Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Neurodegenerative Disease market in any manner.
Global Neurodegenerative Disease Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Market Segmentation (by Type)
NMDA
SSRIs
Dopamine Inhibitors
Market Segmentation (by Application)
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Neurodegenerative Disease Market
- Overview of the regional outlook of the Neurodegenerative Disease Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurodegenerative Disease Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Neurodegenerative Disease
1.2 Key Market Segments
1.2.1 Neurodegenerative Disease Segment by Type
1.2.2 Neurodegenerative Disease Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEURODEGENERATIVE DISEASE MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neurodegenerative Disease Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Neurodegenerative Disease Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEURODEGENERATIVE DISEASE MARKET COMPETITIVE LANDSCAPE
3.1 Global Neurodegenerative Disease Sales by Manufacturers (2019-2024)
3.2 Global Neurodegenerative Disease Revenue Market Share by Manufacturers (2019-2024)
3.3 Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Neurodegenerative Disease Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Neurodegenerative Disease Sales Sites, Area Served, Product Type
3.6 Neurodegenerative Disease Market Competitive Situation and Trends
3.6.1 Neurodegenerative Disease Market Concentration Rate
3.6.2 Global 5 and 10 Largest Neurodegenerative Disease Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NEURODEGENERATIVE DISEASE INDUSTRY CHAIN ANALYSIS
4.1 Neurodegenerative Disease Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEURODEGENERATIVE DISEASE MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NEURODEGENERATIVE DISEASE MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurodegenerative Disease Sales Market Share by Type (2019-2024)
6.3 Global Neurodegenerative Disease Market Size Market Share by Type (2019-2024)
6.4 Global Neurodegenerative Disease Price by Type (2019-2024)
7 NEURODEGENERATIVE DISEASE MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurodegenerative Disease Market Sales by Application (2019-2024)
7.3 Global Neurodegenerative Disease Market Size (M USD) by Application (2019-2024)
7.4 Global Neurodegenerative Disease Sales Growth Rate by Application (2019-2024)
8 NEURODEGENERATIVE DISEASE MARKET SEGMENTATION BY REGION
8.1 Global Neurodegenerative Disease Sales by Region
8.1.1 Global Neurodegenerative Disease Sales by Region
8.1.2 Global Neurodegenerative Disease Sales Market Share by Region
8.2 North America
8.2.1 North America Neurodegenerative Disease Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Neurodegenerative Disease Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Neurodegenerative Disease Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Neurodegenerative Disease Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Neurodegenerative Disease Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Novartis
9.1.1 Novartis Neurodegenerative Disease Basic Information
9.1.2 Novartis Neurodegenerative Disease Product Overview
9.1.3 Novartis Neurodegenerative Disease Product Market Performance
9.1.4 Novartis Business Overview
9.1.5 Novartis Neurodegenerative Disease SWOT Analysis
9.1.6 Novartis Recent Developments
9.2 Pfizer
9.2.1 Pfizer Neurodegenerative Disease Basic Information
9.2.2 Pfizer Neurodegenerative Disease Product Overview
9.2.3 Pfizer Neurodegenerative Disease Product Market Performance
9.2.4 Pfizer Business Overview
9.2.5 Pfizer Neurodegenerative Disease SWOT Analysis
9.2.6 Pfizer Recent Developments
9.3 Merck Serono
9.3.1 Merck Serono Neurodegenerative Disease Basic Information
9.3.2 Merck Serono Neurodegenerative Disease Product Overview
9.3.3 Merck Serono Neurodegenerative Disease Product Market Performance
9.3.4 Merck Serono Neurodegenerative Disease SWOT Analysis
9.3.5 Merck Serono Business Overview
9.3.6 Merck Serono Recent Developments
9.4 Biogen Idec
9.4.1 Biogen Idec Neurodegenerative Disease Basic Information
9.4.2 Biogen Idec Neurodegenerative Disease Product Overview
9.4.3 Biogen Idec Neurodegenerative Disease Product Market Performance
9.4.4 Biogen Idec Business Overview
9.4.5 Biogen Idec Recent Developments
9.5 TEVA
9.5.1 TEVA Neurodegenerative Disease Basic Information
9.5.2 TEVA Neurodegenerative Disease Product Overview
9.5.3 TEVA Neurodegenerative Disease Product Market Performance
9.5.4 TEVA Business Overview
9.5.5 TEVA Recent Developments
9.6 UCB
9.6.1 UCB Neurodegenerative Disease Basic Information
9.6.2 UCB Neurodegenerative Disease Product Overview
9.6.3 UCB Neurodegenerative Disease Product Market Performance
9.6.4 UCB Business Overview
9.6.5 UCB Recent Developments
9.7 Boehringer Ingelheim
9.7.1 Boehringer Ingelheim Neurodegenerative Disease Basic Information
9.7.2 Boehringer Ingelheim Neurodegenerative Disease Product Overview
9.7.3 Boehringer Ingelheim Neurodegenerative Disease Product Market Performance
9.7.4 Boehringer Ingelheim Business Overview
9.7.5 Boehringer Ingelheim Recent Developments
9.8 Sanofi
9.8.1 Sanofi Neurodegenerative Disease Basic Information
9.8.2 Sanofi Neurodegenerative Disease Product Overview
9.8.3 Sanofi Neurodegenerative Disease Product Market Performance
9.8.4 Sanofi Business Overview
9.8.5 Sanofi Recent Developments
9.9 GlaxoSmithKline
9.9.1 GlaxoSmithKline Neurodegenerative Disease Basic Information
9.9.2 GlaxoSmithKline Neurodegenerative Disease Product Overview
9.9.3 GlaxoSmithKline Neurodegenerative Disease Product Market Performance
9.9.4 GlaxoSmithKline Business Overview
9.9.5 GlaxoSmithKline Recent Developments
9.10 Livzon Pharmaceutical
9.10.1 Livzon Pharmaceutical Neurodegenerative Disease Basic Information
9.10.2 Livzon Pharmaceutical Neurodegenerative Disease Product Overview
9.10.3 Livzon Pharmaceutical Neurodegenerative Disease Product Market Performance
9.10.4 Livzon Pharmaceutical Business Overview
9.10.5 Livzon Pharmaceutical Recent Developments
9.11 Haisco Pharmaceutical
9.11.1 Haisco Pharmaceutical Neurodegenerative Disease Basic Information
9.11.2 Haisco Pharmaceutical Neurodegenerative Disease Product Overview
9.11.3 Haisco Pharmaceutical Neurodegenerative Disease Product Market Performance
9.11.4 Haisco Pharmaceutical Business Overview
9.11.5 Haisco Pharmaceutical Recent Developments
9.12 Jingxin Pharmaceutical
9.12.1 Jingxin Pharmaceutical Neurodegenerative Disease Basic Information
9.12.2 Jingxin Pharmaceutical Neurodegenerative Disease Product Overview
9.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Product Market Performance
9.12.4 Jingxin Pharmaceutical Business Overview
9.12.5 Jingxin Pharmaceutical Recent Developments
9.13 Dongcheng Biochemicals
9.13.1 Dongcheng Biochemicals Neurodegenerative Disease Basic Information
9.13.2 Dongcheng Biochemicals Neurodegenerative Disease Product Overview
9.13.3 Dongcheng Biochemicals Neurodegenerative Disease Product Market Performance
9.13.4 Dongcheng Biochemicals Business Overview
9.13.5 Dongcheng Biochemicals Recent Developments
9.14 Hisun Pharmaceutical
9.14.1 Hisun Pharmaceutical Neurodegenerative Disease Basic Information
9.14.2 Hisun Pharmaceutical Neurodegenerative Disease Product Overview
9.14.3 Hisun Pharmaceutical Neurodegenerative Disease Product Market Performance
9.14.4 Hisun Pharmaceutical Business Overview
9.14.5 Hisun Pharmaceutical Recent Developments
9.15 Luye Pharma
9.15.1 Luye Pharma Neurodegenerative Disease Basic Information
9.15.2 Luye Pharma Neurodegenerative Disease Product Overview
9.15.3 Luye Pharma Neurodegenerative Disease Product Market Performance
9.15.4 Luye Pharma Business Overview
9.15.5 Luye Pharma Recent Developments
9.16 Ark Pharmaceutical
9.16.1 Ark Pharmaceutical Neurodegenerative Disease Basic Information
9.16.2 Ark Pharmaceutical Neurodegenerative Disease Product Overview
9.16.3 Ark Pharmaceutical Neurodegenerative Disease Product Market Performance
9.16.4 Ark Pharmaceutical Business Overview
9.16.5 Ark Pharmaceutical Recent Developments
9.17 Kanghong Pharmaceutical
9.17.1 Kanghong Pharmaceutical Neurodegenerative Disease Basic Information
9.17.2 Kanghong Pharmaceutical Neurodegenerative Disease Product Overview
9.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Product Market Performance
9.17.4 Kanghong Pharmaceutical Business Overview
9.17.5 Kanghong Pharmaceutical Recent Developments
9.18 Huahai Pharmaceutical
9.18.1 Huahai Pharmaceutical Neurodegenerative Disease Basic Information
9.18.2 Huahai Pharmaceutical Neurodegenerative Disease Product Overview
9.18.3 Huahai Pharmaceutical Neurodegenerative Disease Product Market Performance
9.18.4 Huahai Pharmaceutical Business Overview
9.18.5 Huahai Pharmaceutical Recent Developments
9.19 BORA PHARMACEUTICALS
9.19.1 BORA PHARMACEUTICALS Neurodegenerative Disease Basic Information
9.19.2 BORA PHARMACEUTICALS Neurodegenerative Disease Product Overview
9.19.3 BORA PHARMACEUTICALS Neurodegenerative Disease Product Market Performance
9.19.4 BORA PHARMACEUTICALS Business Overview
9.19.5 BORA PHARMACEUTICALS Recent Developments
10 NEURODEGENERATIVE DISEASE MARKET FORECAST BY REGION
10.1 Global Neurodegenerative Disease Market Size Forecast
10.2 Global Neurodegenerative Disease Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Neurodegenerative Disease Market Size Forecast by Country
10.2.3 Asia Pacific Neurodegenerative Disease Market Size Forecast by Region
10.2.4 South America Neurodegenerative Disease Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Neurodegenerative Disease by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Neurodegenerative Disease Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Neurodegenerative Disease by Type (2025-2030)
11.1.2 Global Neurodegenerative Disease Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Neurodegenerative Disease by Type (2025-2030)
11.2 Global Neurodegenerative Disease Market Forecast by Application (2025-2030)
11.2.1 Global Neurodegenerative Disease Sales (Kilotons) Forecast by Application
11.2.2 Global Neurodegenerative Disease Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Neurodegenerative Disease
1.2 Key Market Segments
1.2.1 Neurodegenerative Disease Segment by Type
1.2.2 Neurodegenerative Disease Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEURODEGENERATIVE DISEASE MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neurodegenerative Disease Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Neurodegenerative Disease Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEURODEGENERATIVE DISEASE MARKET COMPETITIVE LANDSCAPE
3.1 Global Neurodegenerative Disease Sales by Manufacturers (2019-2024)
3.2 Global Neurodegenerative Disease Revenue Market Share by Manufacturers (2019-2024)
3.3 Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Neurodegenerative Disease Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Neurodegenerative Disease Sales Sites, Area Served, Product Type
3.6 Neurodegenerative Disease Market Competitive Situation and Trends
3.6.1 Neurodegenerative Disease Market Concentration Rate
3.6.2 Global 5 and 10 Largest Neurodegenerative Disease Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NEURODEGENERATIVE DISEASE INDUSTRY CHAIN ANALYSIS
4.1 Neurodegenerative Disease Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEURODEGENERATIVE DISEASE MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NEURODEGENERATIVE DISEASE MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neurodegenerative Disease Sales Market Share by Type (2019-2024)
6.3 Global Neurodegenerative Disease Market Size Market Share by Type (2019-2024)
6.4 Global Neurodegenerative Disease Price by Type (2019-2024)
7 NEURODEGENERATIVE DISEASE MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neurodegenerative Disease Market Sales by Application (2019-2024)
7.3 Global Neurodegenerative Disease Market Size (M USD) by Application (2019-2024)
7.4 Global Neurodegenerative Disease Sales Growth Rate by Application (2019-2024)
8 NEURODEGENERATIVE DISEASE MARKET SEGMENTATION BY REGION
8.1 Global Neurodegenerative Disease Sales by Region
8.1.1 Global Neurodegenerative Disease Sales by Region
8.1.2 Global Neurodegenerative Disease Sales Market Share by Region
8.2 North America
8.2.1 North America Neurodegenerative Disease Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Neurodegenerative Disease Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Neurodegenerative Disease Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Neurodegenerative Disease Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Neurodegenerative Disease Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Novartis
9.1.1 Novartis Neurodegenerative Disease Basic Information
9.1.2 Novartis Neurodegenerative Disease Product Overview
9.1.3 Novartis Neurodegenerative Disease Product Market Performance
9.1.4 Novartis Business Overview
9.1.5 Novartis Neurodegenerative Disease SWOT Analysis
9.1.6 Novartis Recent Developments
9.2 Pfizer
9.2.1 Pfizer Neurodegenerative Disease Basic Information
9.2.2 Pfizer Neurodegenerative Disease Product Overview
9.2.3 Pfizer Neurodegenerative Disease Product Market Performance
9.2.4 Pfizer Business Overview
9.2.5 Pfizer Neurodegenerative Disease SWOT Analysis
9.2.6 Pfizer Recent Developments
9.3 Merck Serono
9.3.1 Merck Serono Neurodegenerative Disease Basic Information
9.3.2 Merck Serono Neurodegenerative Disease Product Overview
9.3.3 Merck Serono Neurodegenerative Disease Product Market Performance
9.3.4 Merck Serono Neurodegenerative Disease SWOT Analysis
9.3.5 Merck Serono Business Overview
9.3.6 Merck Serono Recent Developments
9.4 Biogen Idec
9.4.1 Biogen Idec Neurodegenerative Disease Basic Information
9.4.2 Biogen Idec Neurodegenerative Disease Product Overview
9.4.3 Biogen Idec Neurodegenerative Disease Product Market Performance
9.4.4 Biogen Idec Business Overview
9.4.5 Biogen Idec Recent Developments
9.5 TEVA
9.5.1 TEVA Neurodegenerative Disease Basic Information
9.5.2 TEVA Neurodegenerative Disease Product Overview
9.5.3 TEVA Neurodegenerative Disease Product Market Performance
9.5.4 TEVA Business Overview
9.5.5 TEVA Recent Developments
9.6 UCB
9.6.1 UCB Neurodegenerative Disease Basic Information
9.6.2 UCB Neurodegenerative Disease Product Overview
9.6.3 UCB Neurodegenerative Disease Product Market Performance
9.6.4 UCB Business Overview
9.6.5 UCB Recent Developments
9.7 Boehringer Ingelheim
9.7.1 Boehringer Ingelheim Neurodegenerative Disease Basic Information
9.7.2 Boehringer Ingelheim Neurodegenerative Disease Product Overview
9.7.3 Boehringer Ingelheim Neurodegenerative Disease Product Market Performance
9.7.4 Boehringer Ingelheim Business Overview
9.7.5 Boehringer Ingelheim Recent Developments
9.8 Sanofi
9.8.1 Sanofi Neurodegenerative Disease Basic Information
9.8.2 Sanofi Neurodegenerative Disease Product Overview
9.8.3 Sanofi Neurodegenerative Disease Product Market Performance
9.8.4 Sanofi Business Overview
9.8.5 Sanofi Recent Developments
9.9 GlaxoSmithKline
9.9.1 GlaxoSmithKline Neurodegenerative Disease Basic Information
9.9.2 GlaxoSmithKline Neurodegenerative Disease Product Overview
9.9.3 GlaxoSmithKline Neurodegenerative Disease Product Market Performance
9.9.4 GlaxoSmithKline Business Overview
9.9.5 GlaxoSmithKline Recent Developments
9.10 Livzon Pharmaceutical
9.10.1 Livzon Pharmaceutical Neurodegenerative Disease Basic Information
9.10.2 Livzon Pharmaceutical Neurodegenerative Disease Product Overview
9.10.3 Livzon Pharmaceutical Neurodegenerative Disease Product Market Performance
9.10.4 Livzon Pharmaceutical Business Overview
9.10.5 Livzon Pharmaceutical Recent Developments
9.11 Haisco Pharmaceutical
9.11.1 Haisco Pharmaceutical Neurodegenerative Disease Basic Information
9.11.2 Haisco Pharmaceutical Neurodegenerative Disease Product Overview
9.11.3 Haisco Pharmaceutical Neurodegenerative Disease Product Market Performance
9.11.4 Haisco Pharmaceutical Business Overview
9.11.5 Haisco Pharmaceutical Recent Developments
9.12 Jingxin Pharmaceutical
9.12.1 Jingxin Pharmaceutical Neurodegenerative Disease Basic Information
9.12.2 Jingxin Pharmaceutical Neurodegenerative Disease Product Overview
9.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Product Market Performance
9.12.4 Jingxin Pharmaceutical Business Overview
9.12.5 Jingxin Pharmaceutical Recent Developments
9.13 Dongcheng Biochemicals
9.13.1 Dongcheng Biochemicals Neurodegenerative Disease Basic Information
9.13.2 Dongcheng Biochemicals Neurodegenerative Disease Product Overview
9.13.3 Dongcheng Biochemicals Neurodegenerative Disease Product Market Performance
9.13.4 Dongcheng Biochemicals Business Overview
9.13.5 Dongcheng Biochemicals Recent Developments
9.14 Hisun Pharmaceutical
9.14.1 Hisun Pharmaceutical Neurodegenerative Disease Basic Information
9.14.2 Hisun Pharmaceutical Neurodegenerative Disease Product Overview
9.14.3 Hisun Pharmaceutical Neurodegenerative Disease Product Market Performance
9.14.4 Hisun Pharmaceutical Business Overview
9.14.5 Hisun Pharmaceutical Recent Developments
9.15 Luye Pharma
9.15.1 Luye Pharma Neurodegenerative Disease Basic Information
9.15.2 Luye Pharma Neurodegenerative Disease Product Overview
9.15.3 Luye Pharma Neurodegenerative Disease Product Market Performance
9.15.4 Luye Pharma Business Overview
9.15.5 Luye Pharma Recent Developments
9.16 Ark Pharmaceutical
9.16.1 Ark Pharmaceutical Neurodegenerative Disease Basic Information
9.16.2 Ark Pharmaceutical Neurodegenerative Disease Product Overview
9.16.3 Ark Pharmaceutical Neurodegenerative Disease Product Market Performance
9.16.4 Ark Pharmaceutical Business Overview
9.16.5 Ark Pharmaceutical Recent Developments
9.17 Kanghong Pharmaceutical
9.17.1 Kanghong Pharmaceutical Neurodegenerative Disease Basic Information
9.17.2 Kanghong Pharmaceutical Neurodegenerative Disease Product Overview
9.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Product Market Performance
9.17.4 Kanghong Pharmaceutical Business Overview
9.17.5 Kanghong Pharmaceutical Recent Developments
9.18 Huahai Pharmaceutical
9.18.1 Huahai Pharmaceutical Neurodegenerative Disease Basic Information
9.18.2 Huahai Pharmaceutical Neurodegenerative Disease Product Overview
9.18.3 Huahai Pharmaceutical Neurodegenerative Disease Product Market Performance
9.18.4 Huahai Pharmaceutical Business Overview
9.18.5 Huahai Pharmaceutical Recent Developments
9.19 BORA PHARMACEUTICALS
9.19.1 BORA PHARMACEUTICALS Neurodegenerative Disease Basic Information
9.19.2 BORA PHARMACEUTICALS Neurodegenerative Disease Product Overview
9.19.3 BORA PHARMACEUTICALS Neurodegenerative Disease Product Market Performance
9.19.4 BORA PHARMACEUTICALS Business Overview
9.19.5 BORA PHARMACEUTICALS Recent Developments
10 NEURODEGENERATIVE DISEASE MARKET FORECAST BY REGION
10.1 Global Neurodegenerative Disease Market Size Forecast
10.2 Global Neurodegenerative Disease Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Neurodegenerative Disease Market Size Forecast by Country
10.2.3 Asia Pacific Neurodegenerative Disease Market Size Forecast by Region
10.2.4 South America Neurodegenerative Disease Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Neurodegenerative Disease by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Neurodegenerative Disease Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Neurodegenerative Disease by Type (2025-2030)
11.1.2 Global Neurodegenerative Disease Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Neurodegenerative Disease by Type (2025-2030)
11.2 Global Neurodegenerative Disease Market Forecast by Application (2025-2030)
11.2.1 Global Neurodegenerative Disease Sales (Kilotons) Forecast by Application
11.2.2 Global Neurodegenerative Disease Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Neurodegenerative Disease Market Size Comparison by Region (M USD)
Table 5. Global Neurodegenerative Disease Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Neurodegenerative Disease Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Neurodegenerative Disease Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Neurodegenerative Disease Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2022)
Table 10. Global Market Neurodegenerative Disease Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Neurodegenerative Disease Sales Sites and Area Served
Table 12. Manufacturers Neurodegenerative Disease Product Type
Table 13. Global Neurodegenerative Disease Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Neurodegenerative Disease
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neurodegenerative Disease Market Challenges
Table 22. Global Neurodegenerative Disease Sales by Type (Kilotons)
Table 23. Global Neurodegenerative Disease Market Size by Type (M USD)
Table 24. Global Neurodegenerative Disease Sales (Kilotons) by Type (2019-2024)
Table 25. Global Neurodegenerative Disease Sales Market Share by Type (2019-2024)
Table 26. Global Neurodegenerative Disease Market Size (M USD) by Type (2019-2024)
Table 27. Global Neurodegenerative Disease Market Size Share by Type (2019-2024)
Table 28. Global Neurodegenerative Disease Price (USD/Ton) by Type (2019-2024)
Table 29. Global Neurodegenerative Disease Sales (Kilotons) by Application
Table 30. Global Neurodegenerative Disease Market Size by Application
Table 31. Global Neurodegenerative Disease Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Neurodegenerative Disease Sales Market Share by Application (2019-2024)
Table 33. Global Neurodegenerative Disease Sales by Application (2019-2024) & (M USD)
Table 34. Global Neurodegenerative Disease Market Share by Application (2019-2024)
Table 35. Global Neurodegenerative Disease Sales Growth Rate by Application (2019-2024)
Table 36. Global Neurodegenerative Disease Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Neurodegenerative Disease Sales Market Share by Region (2019-2024)
Table 38. North America Neurodegenerative Disease Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Neurodegenerative Disease Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Neurodegenerative Disease Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Neurodegenerative Disease Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Neurodegenerative Disease Sales by Region (2019-2024) & (Kilotons)
Table 43. Novartis Neurodegenerative Disease Basic Information
Table 44. Novartis Neurodegenerative Disease Product Overview
Table 45. Novartis Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Novartis Business Overview
Table 47. Novartis Neurodegenerative Disease SWOT Analysis
Table 48. Novartis Recent Developments
Table 49. Pfizer Neurodegenerative Disease Basic Information
Table 50. Pfizer Neurodegenerative Disease Product Overview
Table 51. Pfizer Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Pfizer Business Overview
Table 53. Pfizer Neurodegenerative Disease SWOT Analysis
Table 54. Pfizer Recent Developments
Table 55. Merck Serono Neurodegenerative Disease Basic Information
Table 56. Merck Serono Neurodegenerative Disease Product Overview
Table 57. Merck Serono Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Merck Serono Neurodegenerative Disease SWOT Analysis
Table 59. Merck Serono Business Overview
Table 60. Merck Serono Recent Developments
Table 61. Biogen Idec Neurodegenerative Disease Basic Information
Table 62. Biogen Idec Neurodegenerative Disease Product Overview
Table 63. Biogen Idec Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Biogen Idec Business Overview
Table 65. Biogen Idec Recent Developments
Table 66. TEVA Neurodegenerative Disease Basic Information
Table 67. TEVA Neurodegenerative Disease Product Overview
Table 68. TEVA Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. TEVA Business Overview
Table 70. TEVA Recent Developments
Table 71. UCB Neurodegenerative Disease Basic Information
Table 72. UCB Neurodegenerative Disease Product Overview
Table 73. UCB Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. UCB Business Overview
Table 75. UCB Recent Developments
Table 76. Boehringer Ingelheim Neurodegenerative Disease Basic Information
Table 77. Boehringer Ingelheim Neurodegenerative Disease Product Overview
Table 78. Boehringer Ingelheim Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Boehringer Ingelheim Business Overview
Table 80. Boehringer Ingelheim Recent Developments
Table 81. Sanofi Neurodegenerative Disease Basic Information
Table 82. Sanofi Neurodegenerative Disease Product Overview
Table 83. Sanofi Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Sanofi Business Overview
Table 85. Sanofi Recent Developments
Table 86. GlaxoSmithKline Neurodegenerative Disease Basic Information
Table 87. GlaxoSmithKline Neurodegenerative Disease Product Overview
Table 88. GlaxoSmithKline Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. GlaxoSmithKline Business Overview
Table 90. GlaxoSmithKline Recent Developments
Table 91. Livzon Pharmaceutical Neurodegenerative Disease Basic Information
Table 92. Livzon Pharmaceutical Neurodegenerative Disease Product Overview
Table 93. Livzon Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Livzon Pharmaceutical Business Overview
Table 95. Livzon Pharmaceutical Recent Developments
Table 96. Haisco Pharmaceutical Neurodegenerative Disease Basic Information
Table 97. Haisco Pharmaceutical Neurodegenerative Disease Product Overview
Table 98. Haisco Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Haisco Pharmaceutical Business Overview
Table 100. Haisco Pharmaceutical Recent Developments
Table 101. Jingxin Pharmaceutical Neurodegenerative Disease Basic Information
Table 102. Jingxin Pharmaceutical Neurodegenerative Disease Product Overview
Table 103. Jingxin Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Jingxin Pharmaceutical Business Overview
Table 105. Jingxin Pharmaceutical Recent Developments
Table 106. Dongcheng Biochemicals Neurodegenerative Disease Basic Information
Table 107. Dongcheng Biochemicals Neurodegenerative Disease Product Overview
Table 108. Dongcheng Biochemicals Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Dongcheng Biochemicals Business Overview
Table 110. Dongcheng Biochemicals Recent Developments
Table 111. Hisun Pharmaceutical Neurodegenerative Disease Basic Information
Table 112. Hisun Pharmaceutical Neurodegenerative Disease Product Overview
Table 113. Hisun Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Hisun Pharmaceutical Business Overview
Table 115. Hisun Pharmaceutical Recent Developments
Table 116. Luye Pharma Neurodegenerative Disease Basic Information
Table 117. Luye Pharma Neurodegenerative Disease Product Overview
Table 118. Luye Pharma Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 119. Luye Pharma Business Overview
Table 120. Luye Pharma Recent Developments
Table 121. Ark Pharmaceutical Neurodegenerative Disease Basic Information
Table 122. Ark Pharmaceutical Neurodegenerative Disease Product Overview
Table 123. Ark Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 124. Ark Pharmaceutical Business Overview
Table 125. Ark Pharmaceutical Recent Developments
Table 126. Kanghong Pharmaceutical Neurodegenerative Disease Basic Information
Table 127. Kanghong Pharmaceutical Neurodegenerative Disease Product Overview
Table 128. Kanghong Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 129. Kanghong Pharmaceutical Business Overview
Table 130. Kanghong Pharmaceutical Recent Developments
Table 131. Huahai Pharmaceutical Neurodegenerative Disease Basic Information
Table 132. Huahai Pharmaceutical Neurodegenerative Disease Product Overview
Table 133. Huahai Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 134. Huahai Pharmaceutical Business Overview
Table 135. Huahai Pharmaceutical Recent Developments
Table 136. BORA PHARMACEUTICALS Neurodegenerative Disease Basic Information
Table 137. BORA PHARMACEUTICALS Neurodegenerative Disease Product Overview
Table 138. BORA PHARMACEUTICALS Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 139. BORA PHARMACEUTICALS Business Overview
Table 140. BORA PHARMACEUTICALS Recent Developments
Table 141. Global Neurodegenerative Disease Sales Forecast by Region (2025-2030) & (Kilotons)
Table 142. Global Neurodegenerative Disease Market Size Forecast by Region (2025-2030) & (M USD)
Table 143. North America Neurodegenerative Disease Sales Forecast by Country (2025-2030) & (Kilotons)
Table 144. North America Neurodegenerative Disease Market Size Forecast by Country (2025-2030) & (M USD)
Table 145. Europe Neurodegenerative Disease Sales Forecast by Country (2025-2030) & (Kilotons)
Table 146. Europe Neurodegenerative Disease Market Size Forecast by Country (2025-2030) & (M USD)
Table 147. Asia Pacific Neurodegenerative Disease Sales Forecast by Region (2025-2030) & (Kilotons)
Table 148. Asia Pacific Neurodegenerative Disease Market Size Forecast by Region (2025-2030) & (M USD)
Table 149. South America Neurodegenerative Disease Sales Forecast by Country (2025-2030) & (Kilotons)
Table 150. South America Neurodegenerative Disease Market Size Forecast by Country (2025-2030) & (M USD)
Table 151. Middle East and Africa Neurodegenerative Disease Consumption Forecast by Country (2025-2030) & (Units)
Table 152. Middle East and Africa Neurodegenerative Disease Market Size Forecast by Country (2025-2030) & (M USD)
Table 153. Global Neurodegenerative Disease Sales Forecast by Type (2025-2030) & (Kilotons)
Table 154. Global Neurodegenerative Disease Market Size Forecast by Type (2025-2030) & (M USD)
Table 155. Global Neurodegenerative Disease Price Forecast by Type (2025-2030) & (USD/Ton)
Table 156. Global Neurodegenerative Disease Sales (Kilotons) Forecast by Application (2025-2030)
Table 157. Global Neurodegenerative Disease Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Neurodegenerative Disease Market Size Comparison by Region (M USD)
Table 5. Global Neurodegenerative Disease Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Neurodegenerative Disease Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Neurodegenerative Disease Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Neurodegenerative Disease Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2022)
Table 10. Global Market Neurodegenerative Disease Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Neurodegenerative Disease Sales Sites and Area Served
Table 12. Manufacturers Neurodegenerative Disease Product Type
Table 13. Global Neurodegenerative Disease Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Neurodegenerative Disease
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neurodegenerative Disease Market Challenges
Table 22. Global Neurodegenerative Disease Sales by Type (Kilotons)
Table 23. Global Neurodegenerative Disease Market Size by Type (M USD)
Table 24. Global Neurodegenerative Disease Sales (Kilotons) by Type (2019-2024)
Table 25. Global Neurodegenerative Disease Sales Market Share by Type (2019-2024)
Table 26. Global Neurodegenerative Disease Market Size (M USD) by Type (2019-2024)
Table 27. Global Neurodegenerative Disease Market Size Share by Type (2019-2024)
Table 28. Global Neurodegenerative Disease Price (USD/Ton) by Type (2019-2024)
Table 29. Global Neurodegenerative Disease Sales (Kilotons) by Application
Table 30. Global Neurodegenerative Disease Market Size by Application
Table 31. Global Neurodegenerative Disease Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Neurodegenerative Disease Sales Market Share by Application (2019-2024)
Table 33. Global Neurodegenerative Disease Sales by Application (2019-2024) & (M USD)
Table 34. Global Neurodegenerative Disease Market Share by Application (2019-2024)
Table 35. Global Neurodegenerative Disease Sales Growth Rate by Application (2019-2024)
Table 36. Global Neurodegenerative Disease Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Neurodegenerative Disease Sales Market Share by Region (2019-2024)
Table 38. North America Neurodegenerative Disease Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Neurodegenerative Disease Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Neurodegenerative Disease Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Neurodegenerative Disease Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Neurodegenerative Disease Sales by Region (2019-2024) & (Kilotons)
Table 43. Novartis Neurodegenerative Disease Basic Information
Table 44. Novartis Neurodegenerative Disease Product Overview
Table 45. Novartis Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Novartis Business Overview
Table 47. Novartis Neurodegenerative Disease SWOT Analysis
Table 48. Novartis Recent Developments
Table 49. Pfizer Neurodegenerative Disease Basic Information
Table 50. Pfizer Neurodegenerative Disease Product Overview
Table 51. Pfizer Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Pfizer Business Overview
Table 53. Pfizer Neurodegenerative Disease SWOT Analysis
Table 54. Pfizer Recent Developments
Table 55. Merck Serono Neurodegenerative Disease Basic Information
Table 56. Merck Serono Neurodegenerative Disease Product Overview
Table 57. Merck Serono Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Merck Serono Neurodegenerative Disease SWOT Analysis
Table 59. Merck Serono Business Overview
Table 60. Merck Serono Recent Developments
Table 61. Biogen Idec Neurodegenerative Disease Basic Information
Table 62. Biogen Idec Neurodegenerative Disease Product Overview
Table 63. Biogen Idec Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Biogen Idec Business Overview
Table 65. Biogen Idec Recent Developments
Table 66. TEVA Neurodegenerative Disease Basic Information
Table 67. TEVA Neurodegenerative Disease Product Overview
Table 68. TEVA Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. TEVA Business Overview
Table 70. TEVA Recent Developments
Table 71. UCB Neurodegenerative Disease Basic Information
Table 72. UCB Neurodegenerative Disease Product Overview
Table 73. UCB Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. UCB Business Overview
Table 75. UCB Recent Developments
Table 76. Boehringer Ingelheim Neurodegenerative Disease Basic Information
Table 77. Boehringer Ingelheim Neurodegenerative Disease Product Overview
Table 78. Boehringer Ingelheim Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Boehringer Ingelheim Business Overview
Table 80. Boehringer Ingelheim Recent Developments
Table 81. Sanofi Neurodegenerative Disease Basic Information
Table 82. Sanofi Neurodegenerative Disease Product Overview
Table 83. Sanofi Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Sanofi Business Overview
Table 85. Sanofi Recent Developments
Table 86. GlaxoSmithKline Neurodegenerative Disease Basic Information
Table 87. GlaxoSmithKline Neurodegenerative Disease Product Overview
Table 88. GlaxoSmithKline Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. GlaxoSmithKline Business Overview
Table 90. GlaxoSmithKline Recent Developments
Table 91. Livzon Pharmaceutical Neurodegenerative Disease Basic Information
Table 92. Livzon Pharmaceutical Neurodegenerative Disease Product Overview
Table 93. Livzon Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Livzon Pharmaceutical Business Overview
Table 95. Livzon Pharmaceutical Recent Developments
Table 96. Haisco Pharmaceutical Neurodegenerative Disease Basic Information
Table 97. Haisco Pharmaceutical Neurodegenerative Disease Product Overview
Table 98. Haisco Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Haisco Pharmaceutical Business Overview
Table 100. Haisco Pharmaceutical Recent Developments
Table 101. Jingxin Pharmaceutical Neurodegenerative Disease Basic Information
Table 102. Jingxin Pharmaceutical Neurodegenerative Disease Product Overview
Table 103. Jingxin Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. Jingxin Pharmaceutical Business Overview
Table 105. Jingxin Pharmaceutical Recent Developments
Table 106. Dongcheng Biochemicals Neurodegenerative Disease Basic Information
Table 107. Dongcheng Biochemicals Neurodegenerative Disease Product Overview
Table 108. Dongcheng Biochemicals Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Dongcheng Biochemicals Business Overview
Table 110. Dongcheng Biochemicals Recent Developments
Table 111. Hisun Pharmaceutical Neurodegenerative Disease Basic Information
Table 112. Hisun Pharmaceutical Neurodegenerative Disease Product Overview
Table 113. Hisun Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Hisun Pharmaceutical Business Overview
Table 115. Hisun Pharmaceutical Recent Developments
Table 116. Luye Pharma Neurodegenerative Disease Basic Information
Table 117. Luye Pharma Neurodegenerative Disease Product Overview
Table 118. Luye Pharma Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 119. Luye Pharma Business Overview
Table 120. Luye Pharma Recent Developments
Table 121. Ark Pharmaceutical Neurodegenerative Disease Basic Information
Table 122. Ark Pharmaceutical Neurodegenerative Disease Product Overview
Table 123. Ark Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 124. Ark Pharmaceutical Business Overview
Table 125. Ark Pharmaceutical Recent Developments
Table 126. Kanghong Pharmaceutical Neurodegenerative Disease Basic Information
Table 127. Kanghong Pharmaceutical Neurodegenerative Disease Product Overview
Table 128. Kanghong Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 129. Kanghong Pharmaceutical Business Overview
Table 130. Kanghong Pharmaceutical Recent Developments
Table 131. Huahai Pharmaceutical Neurodegenerative Disease Basic Information
Table 132. Huahai Pharmaceutical Neurodegenerative Disease Product Overview
Table 133. Huahai Pharmaceutical Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 134. Huahai Pharmaceutical Business Overview
Table 135. Huahai Pharmaceutical Recent Developments
Table 136. BORA PHARMACEUTICALS Neurodegenerative Disease Basic Information
Table 137. BORA PHARMACEUTICALS Neurodegenerative Disease Product Overview
Table 138. BORA PHARMACEUTICALS Neurodegenerative Disease Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 139. BORA PHARMACEUTICALS Business Overview
Table 140. BORA PHARMACEUTICALS Recent Developments
Table 141. Global Neurodegenerative Disease Sales Forecast by Region (2025-2030) & (Kilotons)
Table 142. Global Neurodegenerative Disease Market Size Forecast by Region (2025-2030) & (M USD)
Table 143. North America Neurodegenerative Disease Sales Forecast by Country (2025-2030) & (Kilotons)
Table 144. North America Neurodegenerative Disease Market Size Forecast by Country (2025-2030) & (M USD)
Table 145. Europe Neurodegenerative Disease Sales Forecast by Country (2025-2030) & (Kilotons)
Table 146. Europe Neurodegenerative Disease Market Size Forecast by Country (2025-2030) & (M USD)
Table 147. Asia Pacific Neurodegenerative Disease Sales Forecast by Region (2025-2030) & (Kilotons)
Table 148. Asia Pacific Neurodegenerative Disease Market Size Forecast by Region (2025-2030) & (M USD)
Table 149. South America Neurodegenerative Disease Sales Forecast by Country (2025-2030) & (Kilotons)
Table 150. South America Neurodegenerative Disease Market Size Forecast by Country (2025-2030) & (M USD)
Table 151. Middle East and Africa Neurodegenerative Disease Consumption Forecast by Country (2025-2030) & (Units)
Table 152. Middle East and Africa Neurodegenerative Disease Market Size Forecast by Country (2025-2030) & (M USD)
Table 153. Global Neurodegenerative Disease Sales Forecast by Type (2025-2030) & (Kilotons)
Table 154. Global Neurodegenerative Disease Market Size Forecast by Type (2025-2030) & (M USD)
Table 155. Global Neurodegenerative Disease Price Forecast by Type (2025-2030) & (USD/Ton)
Table 156. Global Neurodegenerative Disease Sales (Kilotons) Forecast by Application (2025-2030)
Table 157. Global Neurodegenerative Disease Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Neurodegenerative Disease
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neurodegenerative Disease Market Size (M USD), 2019-2030
Figure 5. Global Neurodegenerative Disease Market Size (M USD) (2019-2030)
Figure 6. Global Neurodegenerative Disease Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neurodegenerative Disease Market Size by Country (M USD)
Figure 11. Neurodegenerative Disease Sales Share by Manufacturers in 2023
Figure 12. Global Neurodegenerative Disease Revenue Share by Manufacturers in 2023
Figure 13. Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Neurodegenerative Disease Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Neurodegenerative Disease Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Neurodegenerative Disease Market Share by Type
Figure 18. Sales Market Share of Neurodegenerative Disease by Type (2019-2024)
Figure 19. Sales Market Share of Neurodegenerative Disease by Type in 2023
Figure 20. Market Size Share of Neurodegenerative Disease by Type (2019-2024)
Figure 21. Market Size Market Share of Neurodegenerative Disease by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Neurodegenerative Disease Market Share by Application
Figure 24. Global Neurodegenerative Disease Sales Market Share by Application (2019-2024)
Figure 25. Global Neurodegenerative Disease Sales Market Share by Application in 2023
Figure 26. Global Neurodegenerative Disease Market Share by Application (2019-2024)
Figure 27. Global Neurodegenerative Disease Market Share by Application in 2023
Figure 28. Global Neurodegenerative Disease Sales Growth Rate by Application (2019-2024)
Figure 29. Global Neurodegenerative Disease Sales Market Share by Region (2019-2024)
Figure 30. North America Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Neurodegenerative Disease Sales Market Share by Country in 2023
Figure 32. U.S. Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Neurodegenerative Disease Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Neurodegenerative Disease Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Neurodegenerative Disease Sales Market Share by Country in 2023
Figure 37. Germany Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Neurodegenerative Disease Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Neurodegenerative Disease Sales Market Share by Region in 2023
Figure 44. China Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Neurodegenerative Disease Sales and Growth Rate (Kilotons)
Figure 50. South America Neurodegenerative Disease Sales Market Share by Country in 2023
Figure 51. Brazil Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Neurodegenerative Disease Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Neurodegenerative Disease Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Neurodegenerative Disease Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Neurodegenerative Disease Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Neurodegenerative Disease Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Neurodegenerative Disease Market Share Forecast by Type (2025-2030)
Figure 65. Global Neurodegenerative Disease Sales Forecast by Application (2025-2030)
Figure 66. Global Neurodegenerative Disease Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Neurodegenerative Disease
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neurodegenerative Disease Market Size (M USD), 2019-2030
Figure 5. Global Neurodegenerative Disease Market Size (M USD) (2019-2030)
Figure 6. Global Neurodegenerative Disease Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neurodegenerative Disease Market Size by Country (M USD)
Figure 11. Neurodegenerative Disease Sales Share by Manufacturers in 2023
Figure 12. Global Neurodegenerative Disease Revenue Share by Manufacturers in 2023
Figure 13. Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Neurodegenerative Disease Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Neurodegenerative Disease Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Neurodegenerative Disease Market Share by Type
Figure 18. Sales Market Share of Neurodegenerative Disease by Type (2019-2024)
Figure 19. Sales Market Share of Neurodegenerative Disease by Type in 2023
Figure 20. Market Size Share of Neurodegenerative Disease by Type (2019-2024)
Figure 21. Market Size Market Share of Neurodegenerative Disease by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Neurodegenerative Disease Market Share by Application
Figure 24. Global Neurodegenerative Disease Sales Market Share by Application (2019-2024)
Figure 25. Global Neurodegenerative Disease Sales Market Share by Application in 2023
Figure 26. Global Neurodegenerative Disease Market Share by Application (2019-2024)
Figure 27. Global Neurodegenerative Disease Market Share by Application in 2023
Figure 28. Global Neurodegenerative Disease Sales Growth Rate by Application (2019-2024)
Figure 29. Global Neurodegenerative Disease Sales Market Share by Region (2019-2024)
Figure 30. North America Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Neurodegenerative Disease Sales Market Share by Country in 2023
Figure 32. U.S. Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Neurodegenerative Disease Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Neurodegenerative Disease Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Neurodegenerative Disease Sales Market Share by Country in 2023
Figure 37. Germany Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Neurodegenerative Disease Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Neurodegenerative Disease Sales Market Share by Region in 2023
Figure 44. China Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Neurodegenerative Disease Sales and Growth Rate (Kilotons)
Figure 50. South America Neurodegenerative Disease Sales Market Share by Country in 2023
Figure 51. Brazil Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Neurodegenerative Disease Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Neurodegenerative Disease Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Neurodegenerative Disease Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Neurodegenerative Disease Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Neurodegenerative Disease Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Neurodegenerative Disease Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Neurodegenerative Disease Market Share Forecast by Type (2025-2030)
Figure 65. Global Neurodegenerative Disease Sales Forecast by Application (2025-2030)
Figure 66. Global Neurodegenerative Disease Market Share Forecast by Application (2025-2030)
